Search

Displaying results 3001 - 3010 of 7497 in total
  1. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    [A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can lead to the development … [A254187] In December 2020, the FDA placed a partial clinical hold and requested the drug developer, Regeneron Pharmaceuticals, to amend clinical protocols to reduce the incidence of CRS.

  2. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    It is subsequently isolated by homogenization of cells and purification by several chromatography steps, including hydrophobic interaction and ion exchange chromatography [FDA Label]. … When activated by thrombin at the site of injury, the FXIII A2B2 pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit.

  3. Drug

    Rasburicase

    go.drugbank.com/drugs/DB00049
    ApprovedInvestigational

    Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain.

  4. Drug

    Noxytiolin

    go.drugbank.com/drugs/DB13838
    Approved

    Local antibacterial that probably acts by releasing formaldehyde in aqueous solutions.

  5. Drug

    Geneticin

    go.drugbank.com/drugs/DB04263
    Experimental

    Resistance to Geneticin is conferred by the neo gene from Tn5 encoding an aminoglycoside 3‘-phosphotransferase, APH 3‘ II. … Geneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea.

  6. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    Clinical development with previous fumagillin derivatives has been limited by their toxicity profile. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases

  7. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. … It contains 6 N-linked oligosaccharide modification sites.

  8. Drug

    Sulfathiazole

    go.drugbank.com/drugs/DB06147
    ApprovedVet approvedWithdrawn

    It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.

    Synonyms: N1-2-Thiazolylsulfanilamide, N(1)-2-Thiazolylsulfanilamide
  9. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. … It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.

  10. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen

    go.drugbank.com/drugs/DB10285
    ApprovedInvestigational

    by *Neisseria meningitidis* serogroup B. … It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily